ZyCoV-D shot can remain stable at room temperature: Zydus Cadila chairman

The company plans to apply for approval once it finishes phase 3 trials


ZyCoV-D is India's first DNA plasmid vaccine

Ahmedabad-based pharma major Cadila Healthcare (Zydus Cadila), which is readying to start phase 3 clinical trials, claimed that its investigational candidate ZyCoV-D can remain stable even at room temperature for

Also Read

Indian samples of global Covid-19 vaccines need to be larger: Experts

Zydus Cadila begins human trials for its Covid-19 vaccine candidate

Coronavirus vaccine update: Mexico gets 1st doses of Chinese vaccine COVAX

Coronavirus vaccine update: Oxford vaccine to provide protection for a year

Coronavirus vaccine update: UK, Russia to rollout vaccine from next week

No pressure on regulator to approve a vaccine, says NITI Aayog's V K Paul

DATA STORY: Global active Covid cases top 20 mn; India's share down to 1.78%

World Coronavirus Dispatch: Dicey nature of investing in oil during Covid

India Coronavirus Dispatch: The utility of smaller hospitals in a pandemic

Borders, Bavaria and bust-ups: How Germany lost its way on Covid-19

First Published: Dec 12 2020 | 5:38 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on are available only to BS Premium subscribers.

Register to